Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fem pH is a therapeutic vaginal gel (jelly) developed and marketed by EDW Pharma (formerly ITF Pharma) through its Women's Choice Pharmaceuticals division. Formulated as a 0.9%-0.025% gel, it typically contains acetic acid and oxyquinoline sulfate as its active components. The drug is designed to restore and maintain normal vaginal acidity (pH balance), creating an environment that prevents the overgrowth of pathogenic yeast and bacteria. It is indicated for vaginal therapeutic use, including the treatment and prevention of bacterial vaginosis, particularly in cases where vaginal acidity is disrupted by factors such as diabetes, hormonal changes, antibiotics, steroids, or lifestyle factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetic acid + oxyquinoline sulfate.